Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia

The antibody conjugate gemtuzumab ozogamicin (GO; Mylotarg(®)) provides targeted therapy of acute myeloid leukemia (AML), with recent approvals for patients with CD33-positive disease at diagnosis or relapse, as monotherapy or combined with chemotherapeutics. While its clinical efficacy is well docu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hååg, Petra, Olsson, Magnus, Forsberg, Jeremy, Lindberg, Marita Lagergren, Stenerlöw, Bo, Zong, Dali, Kanter, Lena, Lewensohn, Rolf, Viktorsson, Kristina, Zhivotovsky, Boris, Stenke, Leif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188552/
https://www.ncbi.nlm.nih.gov/pubmed/35690610
http://dx.doi.org/10.1038/s41420-022-01071-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188552/
https://www.ncbi.nlm.nih.gov/pubmed/35690610
http://dx.doi.org/10.1038/s41420-022-01071-9

Ejemplares similares